USA Archives

News and Trends 13 Oct 2022

Odyssey Therapeutics raises $168M for oncology medicine portfolio

Biotech company Odyssey Therapeutics, Inc. has announced it has raised $168 million in series B financing. Odyssey Therapeutics is working on next generation precision immunomodulators and oncology medicines. The current round brings the total capital raised to $386 million. The proceeds will enable Odyssey to advance its portfolio of precision immunomodulators and oncology medicines in […]

October 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 12 Oct 2022

Boston Cell Standards wins FDA $510K clearance for anatomic pathology controls

A company standardizing cancer diagnostic tissue testing with the first immunohistochemistry (IHC) laboratory reference standards has received $510,000 clearance from the U.S. Food and Drug Administration (FDA). The money will go towards Boston Cell Standards IHControls panel for evaluating breast cancers. The clearance represents regulatory approval. “IHControls represent a giant step forward in standardization in […]

October 12, 2022 - 2 minutesmins - By Liza Laws

News and Trends 12 Oct 2022

SiSaf takes steps with FDA for RNA therapeutic to treat rare genetic skeletal disorders

SiSaf Ltd, an RNA delivery and therapeutics company, is initiating the U.S. FDA Regulatory process to obtain orphan drug designation for SIS-101-ADO. SIS-101-ADO is a siRNA therapeutic for patients with autosomal dominant osteopetrosis type 2 (ADO2), a rare genetic skeletal disorder. The request for orphan drug designation and advancement through the regulatory process that SIS-101-ADO […]

October 12, 2022 - 3 minutesmins - By Jim Cornall

Mike Nally Generate Biomedicines ai drug discovery

Interview 12 Oct 2022

Boosting pharma’s falling productivity with AI in drug discovery

The pharmaceutical industry is struggling with mounting costs of drug development. Generate Biomedicines’ CEO, Michael Nally, outlines the firm’s mission to tackle the trend by making drug discovery scalable. Over the decades, the pharma and biopharma industry has suffered a growing stagnation in productivity. According to a report from University College London in 2018, for […]

October 12, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 12 Oct 2022

Ascidian Therapeutics launches with $50M to rewrite RNA

Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, has been launched. With an initial focus on replacing mutated exons at the RNA level, Ascidian’s technology enables therapeutic targeting of large genes and genes with high mutational variance while maintaining native gene expression patterns and levels. This approach is designed to […]

October 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 Oct 2022

Emergex looks to microneedle patches with Zosano Pharma acquisition

Emergex Vaccines Holding Limited has acquired the assets of California-based company Zosano Pharma Corporation. Emergex is a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines. The assets acquired include intellectual property, license agreements, and manufacturing equipment. They also include Zosano’s proprietary microneedle array […]

October 12, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 11 Oct 2022

TILT Biotherapeutics doses first U.S. patient in ovarian cancer immunotherapy trial

TILT Biotherapeutics says the first U.S. patient has been dosed in its ovarian cancer trial using its oncolytic adenovirus, TILT-123. The company said TILT-123 has the potential to be first-in-class for this indication. The open-label, phase I, dose-escalation, multicenter, and multinational, clinical trial of TILT-123 in combination with MSD’s (a tradename of Merck & Co., […]

October 11, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 11 Oct 2022

Illumina and AstraZeneca look to drug target discovery with ‘pivotal research collaboration’

Illumina Inc. has announced a strategic research collaboration with AstraZeneca to accelerate drug target discovery by combining their work in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise. The collaboration will evaluate whether a combined framework of these technologies can increase the yield and confidence of target discovery to […]

October 11, 2022 - 2 minutesmins - By Jim Cornall

Anastasiia Slynko biotech investment 744x368 1

In Depth 11 Oct 2022

The biggest private biotech investments in September 2022

The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […]

October 11, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 11 Oct 2022

Muna Therapeutics gets $4.9M grant for Parkinson’s disease research

Muna Therapeutics has been awarded a $4.9 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to support ongoing preclinical research and development of novel, brain-exposed, small molecule potassium channel type 1.3 (Kv1.3) blockers to abrogate neuroinflammation driven by disease-associated microglia and enhance neuroprotection as a disease-modifying […]

October 11, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 10 Oct 2022

Evonik and Phathom Pharmaceuticals partner on novel acid-blocker vonoprazan

Evonik has entered into a long-term supply agreement with Phathom Pharmaceuticals, a U.S. biopharma company developing and commercializing new treatments for gastric acid-related diseases. Evonik will produce large-scale volumes of vonoprazan at its FDA-inspected manufacturing sites in Tippecanoe, Indiana, U.S., and Dossenheim, Germany. “The manufacture of vonoprazan requires multi-step syntheses involving complex chemistries. We are […]

October 10, 2022 - 2 minutesmins - By Jim Cornall

More News! 10 Oct 2022

RadioMedix announces a $40 million series A financing for targeted alpha therapy platform

A company committed to advancing treatments for rare and aggressive cancers has received a series A funding of $40 million. Clinical stage biotech, RadioMedix, Inc. announced the agreement with an entity related to Portland Investment Counsel Inc. (Portland), on Friday (October 7). RadioMedix is committed to the advancement of a targeted alpha therapy (TAT) pipeline […]

October 10, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

Odyssey Therapeutics raises $168M for oncology medicine portfolio

Boston Cell Standards wins FDA $510K clearance for anatomic pathology controls

SiSaf takes steps with FDA for RNA therapeutic to treat rare genetic skeletal disorders

Boosting pharma’s falling productivity with AI in drug discovery

Ascidian Therapeutics launches with $50M to rewrite RNA

Emergex looks to microneedle patches with Zosano Pharma acquisition

TILT Biotherapeutics doses first U.S. patient in ovarian cancer immunotherapy trial

Illumina and AstraZeneca look to drug target discovery with ‘pivotal research collaboration’

The biggest private biotech investments in September 2022

Muna Therapeutics gets $4.9M grant for Parkinson’s disease research

Evonik and Phathom Pharmaceuticals partner on novel acid-blocker vonoprazan

RadioMedix announces a $40 million series A financing for targeted alpha therapy platform

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!